p53, mutations, and apoptosis in genistein-exposed human lymphoblastoid cells

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 405, Issue 1, 1998, Pages 41-56

  Morris, Suzanne M ^a   Chen, James J ^b   Domon, Olen E ^a   McGarrity, Lynda J ^a   Bishop, Michelle E ^a   Manjanatha, Mugimane G ^a   Casciano, Daniel A ^a  

^a National Center for Toxicology Research   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Apoptosis; Genistein; Human lymphoblastoid cells; Hypoxanthine phophoribosyl transferase mutations; p53 functional status; Thymidine kinase mutations

Indexed keywords

GENISTEIN; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; ISOFLAVONE DERIVATIVE; PROTEIN P53; THYMIDINE KINASE; TIOGUANINE; TRIFLURIDINE;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG RESISTANCE; FLOW CYTOMETRY; GENE LOCUS; GENOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOBLASTOID CELL LINE; MICRONUCLEUS TEST; MUTATION; PRIORITY JOURNAL; REGRESSION ANALYSIS;

APOPTOSIS; CARCINOGENS; CELL CYCLE; CELL SURVIVAL; CELLS, CULTURED; CLONE CELLS; FLOW CYTOMETRY; GENES, P53; GENISTEIN; HUMANS; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; MICRONUCLEUS TESTS; MUTAGENICITY TESTS; MUTAGENS; MUTATION; THIOGUANINE; TRIFLURIDINE;

MAMMALIA;

EID: 0002028597     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-5107(98)00126-2     Document Type: Article

References (79)

1. [1] S.W. Lowe, E.M. Schmitt, A.W. Smith, B.A. Osborne, T. Jacks, p53 is required for radiation-induced apoptosis in mouse thymocytes, Nature 362 (1993) 847-848.
2. [2] S.W. Lowe, S. Bodis, N. Bardeesy, A. McClathcey, L. Remington, H.E. Ruley, D.E. Fisher, T. Jacks, J. Pelletier, D.E. Housman, Apoptosis and the prognostic significance of p53 mutation, Cold Spring Harbor Symp. Quant. Biol. 59 (1994) 419-426.
3. [3] S.W. Lowe, H.E. Ruley, T. Jacks, D.E. Housman, p53-dependent apoptosis modulates the cytotoxicity of anticancer agents, Cell (1993) 957-967.
4. [4] S.J. Korsemeyer, J.R. Shutter, D.J. Veis, D.E. Merry, Z.N. Oltvai, Bcl-2/bax: a rheostat that regulates an anti-oxidant pathway and cell death, Sem. Canc. Biol. 4 (1993) 327-332.
5. [5] T. Miyashita, J.C. Reed, Bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced glucocorticoids and multiple chemotherapeutic drugs, Cancer Res. 52 (1992) 5407-5411.
6. [6] M. Selvakumaran, H.K. Lin, T. Miyashita, H.G. Wang, S. Krajewski, J.C. Reed, B. Hoffman, D. Liebermann, Immediate up-regulation of bax expression by p53 but not by TGFβ1: a paradigm for distinct apoptotic pathways, Oncogene 9 (1994) 1791-1798.
7. [7] Q. Zhan, S. Fan, I. Bae, C. Guillouf, D.A. Libermann, P.M. O'Conner, A.J. Fornace, Induction of bax by genotoxic stress in human cells correlates with normal p53 status and apoptosis, Oncogene 9 (1994) 3743-3751.
8. [8] M.B. Kastan, O. Onyekwere, D. Sidransky, B. Vogelstein, R.W. Craig, Participation of p53 protein in the cellular response to DNA damage, Cancer Res. 51 (1991) 6304-6311.
9. [9] I.R. Radford, p53 status, DNA double-strand break repair proficiency, and radiation response of mouse lymphoid and myeloid cell lines, Int. J. Rad. Biol. 5 (1994) 557-560.
10. [10] W. Zhen, C.M. Denault, K. Loviscek, S. Walter, L. Geng, A.T.M. Vaughn, The relative radiosensitivity of TK6 and WI-L2-NS lymphoblastoid cells derived from a common source is primarily determined by their p53 mutational status, Mutat. Res. (1995) 85-92.
11. [11] J.B. Little, H. Nagasawa, P.C. Keng, Y. Yu, C.Y. Li, Absence of radiation-induced G1 arrest in two closely related human lymphoblast cell lines that differ in p53 status, J. Biol. Chem. 270 (1995) 11033-11036.
12. [12] S.A. Amundson, F. Xia, K. Wolfson, H.L. Liber, Different cytotoxic and mutagenic responses induced by X-rays in two human lymphoblastoid cell lines derived from a single donor, Mutat. Res. 286 (1993) 233-241.
13. [13] F. Xia, X. Wang, Y.H. Wang, N.M. Tsang, D.W. Yandell, K.T. Kelsey, H.L. Liber, Altered p53 status correlated with differences in sensitivity to radiation-induced mutation and apoptosis in two closely related human lymphoblast lines, Cancer Res. 55 (1995) 12-15.
14. [14] J.L. Schwartz, R. Jordan, B.A. Sedita, M.J. Swennington, J.P. Banath, P.L. Olive, Different sensitivity to cell killing and chromosome mutation induction by gamma rays in two human lymphoblastoid cell lines derived from a single donor: possible role of apoptosis, Mutagenesis 10 (1995) 227-233.
15. [15] E.N. Phillips, F. Xia, K.T. Kelsey, H.L. Liber, Spectra of spontaneous and X-ray-induced mutations at the hprt locus in related human lymphoblast cell lines that express wild-type and mutant p53, Radiat. Res. 143 (1995) 255-262.
16. [16] E.N. Phillips, D. Gebow, H.L. Liber, Spectra of X-ray-induced and spontaneous intragenic HPRT mutations in closely related human cells differentially expressing the p53 tumor suppressor gene, Radiat. Res. 147 (1997) 138-147.
17. 1 promotes susceptibility to mutagenesis, Oncogene 13 (1996) 1489-1497.
18. [18] M. Honma, M. Hayashi, T. Sofuni, Cytotoxic and mutagenic responses to X-rays and chemical mutagens in normal and p53-mutated human lymphoblastoid cells, Mutat. Res. 374 (1997) 89-98.
19. [19] M. Honma, L.-S. Zhang, M. Hayashi, K. Takeshita, Y. Nakagawa, N. Tanaka, T. Sofuni, Illegitimate recombination leading to allelic loss and unbalanced translocation in p53-mutated human lymphoblastoid cells, Mol. Cell. Biol. 17 (1997) 4774-4781.
20. [20] S.A. Amundson, H.L. Liber, A comparison of induced mutation at homologous alleles of the tk locus in human cells: II. Molecular analysis of mutants, Mutat. Res. 267 (1992) 89-95.
21. [21] F. Xia, S.A. Amundson, J.A. Nickloff, H.L. Liber, Different capacities from recombination in closely related human lymphoblastid cell lines with different mutational responses to X-irradiation, Mol. Cell. Biol. 14 (1994) 5850-5857.
22. [22] J.L. Schwartz, R. Jordan, Selective elimination of human lymphoid cells with unstable chromosome aberrations by p53-dependent apoptosis, Carcinogenesis 18 (1997) 201-205.
23. +/- human lymphoblastoid cells, Mutat. Res. 357 (1996) 143-165.
24. [24] K.L. Dobo, C.R. Giver, D.A. Eastmond, H.S. Rumbos, A.J. Grosovsky, Extensive loss of heterozygosity accounts for differential mutation rate on chromosome 17q in human lymphoblasts, Carcinogenesis 10 (1995) 53-58.
25. [25] C.L. Crespi, F.J. Gonzalez, D.T. Steimel, T.R. Turner, H.V. Gelboin, R. Langenbach, A metabolically competent human cell line expressing five cDNAs encoding procarcinogen-activation enzymes: application to mutagenicity testing, Chem. Res. Toxicol. 4 (1991) 566-572.
26. [26] H. Adlercreutz, Phytoestrogens: epidemiology and a possible role in cancer protection, Environ. Health Perspect. 103 (1995) 103-112.
27. [27] M. Messina, S. Barnes, Commentary: the role of soy products in reducing the risk of cancer, J. Natl. Canc. Inst. 83 (1991) 541-546.
28. [28] H.P. Lee, L. Gourley, S.W. Duffy, J. Esteve, J. Lee, N.E. Day, Dietary effects on breast-cancer risk in Singapore, Lancet 337 (1991) 1197-1200.
29. [29] R.K. Severson, A.M.Y. Nomura, J.S. Grove, G.N. Stemmermann, A prospective study of demographics, diet, and prostate cancer among men of Japanese ancestry in Hawaii, Cancer Res. 49 (1989) 1857-1860.
30. [30] H. Adlercreutz, H. Markkanen, S. Wantanabe, Plasma concentrations of phytoestrogens in Japanese men, Lancet 342 (1993) 1209-1210.
31. [31] A.A. Franke, L.J. Custer, C.M. Cerna, K. Narala, Rapid HPLC analysis of dietary phytoestrogens from legumes and from human urine, Proc. Soc. Exp. Biol. Med. 208 (1995) 18-26.
32. [32] S. Barnes, T.G. Peterson, Biochemical targets of the isoflavone in tumor cell lines, Proc. Soc. Exp. Biol. Med. 208 (1995) 103-108.
33. [33] S. Barnes, T.G. Peterson, L. Coward, Rationale for the use of genistein-containing soy matrices in chemoprevention trials for breast and prostate cancer, J. Cell. Biochem. S 22 (1995) 181-197.
34. [34] G. Peterson, S. Barnes, Genistein inhibition of the growth of human breast cancer cells: independence from estrogen receptors and the multi-drug resistance gene, Biochem. Biophys. Res. Commun. 179 (1991) 6661-6667.
35. [35] F. Traganos, B. Ardelt, N. Halko, S. Bruno, Z. Darzynkiewicz, Effects of genistein on the growth and cell cycle progression of normal human lymphocytes and human leukemic MOLT-4 and HL-60 cells, Cancer Res. 52 (1992) 6200-6208.
36. [36] M.C. Pagliacci, F. Spinozzi, G. Migliorati, G. Fumi, M. Smacchia, F. Grignani, C. Riccardi, I. Nicoletti, Genistein inhibits tumour cell growth in vitro but enhances mitochondrial reduction of tetrazolium salts: a further pitfall in the use of the MTT assay for evaluating cell growth and survival, Eur. J. Canc. 29 (1993) 1573-1577.
37. [37] A. Okura, H. Arakawa, H. Oka, T. Yoshinari, Y. Monden, Effect of genistein on topoisomerase activity and on the growth of [val12]Ha-ras-transformed NIH 3T3 cells, Biochem. Biophys. Res. Commun. 157 (1988) 183-189.
38. [38] W. Troll, R. Wiesner, C.J. Shellabarger, S. Holtsman, J.P. Stone, Soybean diet lowers breast tumor incidence in irradiated rats, Carcinogenesis 1 (1980) 469-472.
39. [39] C.A. Lamartiniere, J.B. Moore, N.M. Brown, R. Thompson, M.J. Hardin, S. Barnes, Genistein suppresses mammary cancer in rats, Carcinogenesis 16 (1995) 2833-2840.
40. [40] W.B. Murrill, N.M. Brown, J.-X. Zhang, P.A. Manzolillo, S. Barnes, C.A. Lamartiniere, Prepubertal genistein exposure suppresses mammary cancer and enhances gland differentiation in rats, Carcinogenesis 17 (1996) 1451-1457.
41. [41] A.K. Giri, L.W. Lu, Genetic damage and the inhibition of 7,12-dimethylbenz[a]anthracene-induced genetic damage by the phytoestrogens, genistein and daidzein, in female ICR mice, Cancer Lett. 95 (1995) 125-133.
42. [42] A.A. Tohamy, A.A. El Ghor, N.Z. Moharran, M.M. El-Shazly, Protective role of soybean feeding against the cytogenetical and histopathological effects of dibutylamine and sodium nitrate on bone marrow and liver of mice, Mutat. Res. 360 (1996) 155-163.
43. [43] M.J. McCabe, S. Orrenius, Genistein induces apoptosis in immature thymocytes by inhibiting topoisomerase-II, Biochem. Biophy. Res. Commun. 194 (1993) 944-950.
44. [44] J. Markovits, S. Junqua, F. Goldwasser, A.M. Venuat, C. Luccioni, J. Beaumatin, J.M. Saucier, A. Bernheim, A. Jacquemin-Sablon, Genistein resistance in human leukemic CCRF-CEM cells: selection of a diploid cell line with reduced DNA topoisomerase IIβ isoform, Biochem. Pharm. 50 (1995) 177-186.
45. [45] J. Markovits, C. Linassier, P. Fosse, J. Couprie, J. Pierre, A. Jacquemin-Sablon, J.M. Saucier, J.B. Le Pecq, A.K. Larsen, Inhibitory effects of the tyrosine kinase inhibitor genistein on mammalian topoisomerase II, Cancer Res. 49 (1989) 5111-5117.
46. [46] T. Akiyama, J. Ishida, S. Nakagawa, H. Ogawara, S.-I. Watanabe, N. Itoh, M. Shibuya, Y. Fukami, Genistein, a specific inhibitor of tyrosine-specific protein kinases, J. Biol. Chem. 262 (1987) 5592-5595.
47. [47] A. Constantinou, K. Kiguchi, E. Huberman, Induction of differentiation and DNA strand breakage in human HL-60 cells and K-562 leukemia cells by genistein, Cancer Res. 50 (1990) 2618-2624.
48. [48] Y. Yamashita, S.Z. Kawada, H. Nakano, Induction of mammalian topoisomerase II dependent DNA cleavage by nonintercalative flavonoids, genistein and orobol, Biochem. Pharm. 39 (1990) 737-744.
49. [49] L.F. Liu, DNA topoisomerase poisons as antitumor drugs, Annu. Rev. Biochem. 58 (1989) 351-375.
50. +/- → tk - / -mouse lymphoma mutagenesis assay system, Mutat. Res. 105 (1981) 451-456.
51. +/- mouse lymphoma cells, Mutat. Res. 151 (1985) 161-174.
52. [52] D.L. DeMarini, C.L. Doerr, M.K. Meyer, K.H. Brock, J. Hozier, M.M. Moore, Mutagenicity of m-amsa and o-amsa in mammalian cells due to clastogenic mechanisms: possible role of topoisomerase, Mutagenesis 2 (1987) 349-355.
53. [53] C.L. Doerr, K. Harrington-Brock, M.M. Moore, Micronucleus, chromosome aberration, and small-colony TK mutant analysis to quantitate chromosomal damage in L5178Y mouse lymphoma cells, Mutat. Res. 222 (1989) 191-203.
54. [54] S.M. Morris, O.E. Domon, L.J. McGarrity, J.J. Chen, D.A. Casciano, Programmed cell death and mutation induction in AHH-1 human lymphoblastoid cells exposed to m-amsa, Mutat. Res. 329 (1995) 79-96.
55. [55] C.L. Crespi, W.G. Thilly, Assay for gene mutation in a human lymphoblast line, AHH-1, competent for xenobiotic metabolism, Mutat. Res. 128 (1984) 221-230.
56. +/- human lymphoblastoid cells, Mutat. Res. 357 (1996) 143-165.
57. [57] C.L. Crespi, C.G. Ryan, G.M. Sixas, T.R. Turner, B.W. Penman, Tests for mutagenic activity using mutation assays at two loci in the human lymphoblast cell lines, TK6 and AHH-1, Prog. Mutat. Res. 5 (1985) 197-216.
58. [58] E. Furth, W.G. Thilly, B.W. Penman, H.L. Liber, W.M. Rand, Quantitative assay for mutation in diploid human lymphoblasts using microtiter plates, Anal. Biochem. 110 (1981) 1-8.
59. [59] H. Tinwell, J. Ashby, Comparison of acridine orange and giemsa stains in several mouse bone marrow micronucleus assays - including a triple dose study, Mutagenesis 4 (1989) 476-481.
60. [60] P. Van Hummelen, M. Dirsch-Volders, An improved method for the in vitro micronucleus test using human lymphocytes, Mutagenesis 5 (1990) 203-204.
61. [61] J. Surrales, A. Antoccia, A. Creus, F. Degrassi, F. Peris, C. Tanzarella, N. Xamena, R. Marcos, The effect of cytochlasin-B concentration on the frequency of micronuclei induced by four standard mutagens. Results from two laboratories, Mutagenesis 9 (1994) 347-353.
62. +/- human lymphoblastoid cells exposed to the chromosomal mutagen, m-amsa, Environ. Mol. Mutagen. 27 (1996) 10-18.
63. [63] S.M. Morris, L.J. McGarrity, O.E. Domon, J.J. Chen, W.G. Hinson, T.J. Bucci, A.R. Warbritton, D.A. Casciano, The role of programmed cell death in the toxicity of the mutagens, ethyl methanesulfonate and N-ethyl-N′-nitrososurea, in AHH-1 human lymphoblastoid cells, Mutat. Res. 306 (1994) 19-34.
64. [64] J. McCullagh, J.A. Neldar, Generalized Linear Model, 2nd edn., Chapman & Hall, London, 1989.
65. [65] W.S. El-Diery, T. Tokino, V.E. Velculisci, D.B. Levy, J.M. Trent, D. Lin, W.E. Mercer, K.W. Kinzler, B. Vogelstein, WAF1, a potential mediator of p53 tumor suppression, Cell 75 (1993) 817-825.
66. [66] G. Bakalkin, T. Yakovleva, G. Selivonova, K.P. Magnusson, L. Szekely, E. Kiseleva, G. Klein, L. Terenius, K.G. Wiman, p53 binds single-stranded DNA ends and catalyzes DNA renaturation and strand transfer, Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 413-417.
67. [67] M. Reed, B. Woelker, P. Wang, Y. Wang, M.E. Anderson, P. Tegtmeyer, The C-terminal domain of p53 recognizes DNA damaged by ionizing radiation, Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 9455-9459.
68. [68] K.L. Dobo, D.A. Eastmond, A.J. Grosovsky, The influence of cellular apoptotic capacity on N-nitrosodimethylamine-induced loss of heterozygosity mutations in human cells, Carcinogenesis 18 (1997) 1701-1707.
69. [69] F. Xia, H.L. Liber, The tumor suppressor p53 modifies mutational processes in a human lymphoblastoid cell line, Mutat. Res. 373 (1997) 87-97.
70. [70] N. Rampino, H. Yamamoto, Y. Ionov, Y. Li, H. Sawaii, J.C. Reed, M. Perucho, Somatic frameshift mutations in the bax gene in colon cancers of the microsatellite mutator phenotype, Science 275 (1997) 967-969.
71. [71] S.D. Griffiths, A.R. Clarke, L.E. Healy, G. Ross, A.M. Ford, M.L. Hooper, A.H. Wyllie, M. Greaves, Absence of p53 permits propagation of mutant cells following genotoxic damage, Oncogene 14 (1997) 523-531.
72. [72] K. Yanighara, M. Numoto, H. Tauchi, Y. Akama, H. Yokozaki, E. Tahara, K. Kamiya, T. Seito, Genetic status of p53 and induction of apoptosis by radiation or isoflavones in human gastric carcinoma cell lines, Int. J. Oncol. 9 (1996) 95-102.
73. [73] J. Markovits, A.K. Larsen, E. Segal-Bendirdjian, P. Fosse, J.M. Saucier, A. Gazit, A. Levitzki, K. Umezawa, A. Jacquemin-Sablon, Inhibition of DNA topoisomerases I and II and induction of apoptosis by erbstatin and tryphostin derivatives, Biochem. Pharm. 48 (1994) 549-560.
74. [74] G. Bergamaschi, V. Rosti, M. Danova, L. Ponchio, C. Lucotti, M. Cazzola, Inhibitors of tyrosine phosphorylation induce apoptosis in human leukemic cell lines, Leukemia 7 (1993) 2012-2018.
75. [75] P. Anderson, Kinase cascades regulating entry into apoptosis, Micro. Mol. Biol. Rev. 61 (1997) 33-46.
76. [76] R.S. Chapman, A.D. Whetton, C.M. Chresta, C. Dive, Characterization of drug resistance mediated via the suppression of apoptosis of Abelson protein tyrosine kinase, Mol. Pharm. 48 (1995) 334-343.
77. [77] Q. Chen, R.S.P. Benson, A.D. Whetton, S.R. Brant, M. Donowitz, M.H. Montrose, C. Dive, A.J.M. Watson, Role of acid/base homeostasis in the suppression of apoptosis in haematopoietic cells by v-abl protein tyrosine kinase, J. Cell Sci. 110 (1996) 379-387.
78. [78] A.A. Evans, P.J. Owen-Lynch, A.D. Whetton, C. Dive, Activation of the Abelson tyrosine kinase activity is associated with suppression of apoptosis in hemopoietic cells, Cancer Res. 53 (1993) 1735-1738.
79. [79] F. Spinozzi, C. Pagliacci, G. Miglioati, R. Moraca, F. Grignani, C. Riccardi, I. Nicoletti, The natural tyrosine kinase inhibitor genistein produces cell cycle arrest and apoptosis in jurkat T-leukemia cells, Leuk. Res. 18 (1994) 431-439.